Hims & Hers Health (NYSE:HIMS) saw its stock rise 3.6% on Thursday after unveiling its official launch into the Canadian market—a major milestone in the company’s international expansion roadmap.
The move comes shortly after Hims & Hers acquired Livewell, a Canadian digital health provider focused on weight-loss treatments. The acquisition sets the stage for the company to introduce its full weight-loss program in Canada next year, aligning with the expected arrival of generic semaglutide.
The company said the expansion directly targets a substantial unmet medical need in Canada, where nearly two-thirds of adults are overweight or obese and face barriers such as high costs and limited treatment availability. To support its Canadian operations, Hims & Hers appointed Austin Kouri as General Manager for Canada and Dr. Sandy Van as the region’s Chief Medical Officer.
“Our expansion into Canada is a direct response to critical public health needs, particularly around the obesity crisis,” said Andrew Dudum, co-founder and CEO of Hims & Hers. The acquisition of Livewell was completed in an all-cash transaction funded through the company’s existing balance sheet.
Already active in the U.S. and Europe, Hims & Hers views Canada as the next step in its mission to broaden global access to personalized healthcare. The company plans to expand into additional medical categories within Canada and pursue further international growth as consumer demand for accessible, customized healthcare solutions continues to accelerate.